Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
China's New Cybersecurity Law And Draft Data Localization Measures Expected To Burden Multinational Companies(6/22/2017 )  (Premium)
The Market
Analysis: New Product Additions of 2017 NRDL(6/20/2017 )  (Premium)
Industry News
China's Innovative Medical Withdraws from Investment Deal with Pluristem Therapeutics(6/22/2017 )  (Premium)
Chinese Development Zone and Pakistani University Sign MOU for Drug R&D Collaboration(6/21/2017 )  (free)
Snapshot: Bayer's Urban Hospital Drug Sales Witness 10% Growth in 2016(6/20/2017 )  (Premium)
Sanofi to e-Market Consumer Healthcare Products to the Chinese from Australia(6/20/2017 )  (Premium)
ShangPharma Announces Second Milestone in Move for Chinese Stock Listing(6/20/2017 )  (free)
Regulatory News
CDE Publicizes Batch 20 of Drug Applications To Be Granted Priority Review Status(6/20/2017 )  (Premium)
CFDA Announces Officially Joining the ICH(6/19/2017 )  (Premium)
General Health
Central Government to Support More than 600 Healthcare Institutions(6/21/2017 )  (Premium)
China Establishes National Center for Children's Health(6/20/2017 )  (Premium)
Product/R&D News
Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China(6/22/2017 )  (Premium)
API/Bulk Drug News
Another Chinese API Producer in Data Integrity Mudpool and on U.S. Import Alert(6/22/2017 )  (Premium)
People in the News
Recent Executive Moves(6/22/2017 )  (Premium)
Top News Worldwide
White House Task Force Echoes Pharma Proposals(6/21/2017 )  (Premium)
© Wicon International GroupˇˇSupport by: www.heightow.com Home | Site map | Contact Us | Links